Stiff person syndrome (SPS) is caused by an autoimmune attack on the nervous system that disrupts the brain and spinal cord’s ability to regulate muscle movement. In most cases, the immune system produces antibodies that interfere with a chemical messenger called GABA, which normally keeps muscles relaxed when they’re not in use. Without enough GABA signaling, neurons fire uncontrollably, causing the hallmark rigidity and painful spasms of the condition. SPS is rare, with prevalence estimates ranging from one to two cases per 100,000 people down to one per million.
The Central Problem: Lost Muscle Inhibition
Your muscles work in opposing pairs. When you bend your arm, one muscle contracts while the opposing muscle relaxes. This coordination depends on inhibitory signals in the spinal cord, powered by a neurotransmitter called GABA. In SPS, this inhibition breaks down. The opposing muscle never gets the “relax” signal, so both muscles contract at the same time. The result is extreme stiffness, especially in the trunk and legs, along with sudden, painful spasms that can be severe enough to fracture bones.
Brain imaging studies confirm that people with SPS have significantly reduced GABA levels, particularly in the sensorimotor cortex, the brain region that controls voluntary movement. Spinal fluid testing shows the same deficit. Transcranial magnetic stimulation studies also demonstrate that the motor cortex is abnormally excitable, essentially confirming that the brain’s braking system for movement is compromised at multiple levels.
GAD65 Antibodies: The Most Common Culprit
About 60 to 80 percent of people with classic SPS have high levels of antibodies targeting an enzyme called GAD65 (glutamic acid decarboxylase). This enzyme is responsible for converting glutamate, an excitatory brain chemical, into GABA, the calming one. When antibodies attack GAD65, two things happen: less GABA gets produced, and more glutamate accumulates. The balance tips dramatically toward excitation, leaving neurons in a hyperactive state.
These antibodies appear to act directly at nerve terminals where GABA-producing interneurons release their signals. By depressing GABA release at these junctions, they create neuronal hyperexcitability throughout the spinal cord and brain. The excess glutamate may also lower the seizure threshold, which is why some people with SPS experience epilepsy as well.
GAD65 antibodies aren’t exclusive to SPS. They also appear in type 1 diabetes, because the same enzyme exists in insulin-producing pancreatic cells. This overlap explains why many people with SPS also develop type 1 diabetes, thyroid disease, or other autoimmune conditions. The immune system isn’t targeting just one organ; it’s reacting to a protein found in multiple tissues.
Paraneoplastic SPS: When Cancer Is the Trigger
A smaller subset of SPS cases is paraneoplastic, meaning the condition is triggered by the immune system’s response to a hidden cancer. In these cases, the relevant antibody usually targets a different protein called amphiphysin, which is involved in how nerve cells recycle chemical signals. Breast cancer and small cell lung cancer are the tumors most commonly linked to this form. The immune system attacks the cancer cells but also cross-reacts with similar proteins in the nervous system, producing neurological symptoms that can appear months or even years before the cancer itself is detected.
Paraneoplastic SPS often looks slightly different from the classic form. It tends to affect one or two limbs rather than the whole trunk (a pattern called stiff-limb syndrome) and may not respond as well to standard treatments. Identifying the underlying cancer is critical, because treating the tumor can sometimes improve the neurological symptoms.
Genetic Susceptibility
SPS is not inherited in a straightforward way, but genetics do play a role in who develops it. Certain immune system genes, specifically HLA variants that influence how the body distinguishes self from non-self, increase susceptibility. The HLA haplotype DQA1*03:01-DQB1*03:02-DRB1*04:01 and the DRB1*04:01 allele have been linked to GAD-antibody autoimmunity. These are the same types of immune genes associated with other autoimmune diseases like type 1 diabetes and autoimmune thyroiditis, reinforcing the idea that SPS shares a common autoimmune root with these conditions.
Genetic variants in genes that regulate immune function more broadly also appear to contribute. Having these risk factors doesn’t guarantee someone will develop SPS, but it may explain why the condition clusters with other autoimmune disorders in the same person or family.
What Triggers Spasms Day to Day
Once the autoimmune process is underway, everyday stimuli can set off acute episodes of painful muscle spasms. Common triggers include sudden loud noises, unexpected physical touch, and emotional stress. The sensitivity can be extreme. Some people find that street noises like a car horn are enough to trigger full-body spasms and falls, making it frightening to leave the house. This heightened startle response reflects the underlying loss of inhibitory control: without adequate GABA signaling, the nervous system overreacts to sensory input that a healthy brain would filter out.
Variants of the Condition
SPS exists on a spectrum. Classic SPS involves progressive stiffness in the trunk and limbs, typically starting in the lower back and legs and worsening over months to years. It most frequently appears in people in their 40s and affects women more often than men.
Stiff-limb syndrome is a more limited form that affects one limb, usually a leg. People with this variant are often negative for GAD65 antibodies and may respond less well to treatments that boost GABA activity. Without effective treatment, many become wheelchair users within a median of about 3.5 years.
Progressive encephalomyelitis with rigidity and myoclonus (PERM) is the most severe variant. It includes the stiffness and spasms of SPS plus brainstem involvement: difficulty with eye movements, trouble swallowing, jerking movements (myoclonus), and sometimes altered consciousness. PERM is more common in men, often associated with antibodies against glycine receptors rather than GAD65, and has been reported following infections including Epstein-Barr virus, hepatitis C, and COVID-19. Untreated, it carries a mortality rate as high as 40 percent, but it often responds well to immune-targeted therapy. About 20 percent of PERM cases have a paraneoplastic origin.
Who Gets SPS and Why It’s Hard to Diagnose
SPS typically develops between ages 30 and 60. Because it’s so rare and its symptoms overlap with many other conditions, the average time to diagnosis can stretch for years. Early symptoms, like intermittent back stiffness or occasional spasms, are easily attributed to orthopedic problems, anxiety, or functional neurological disorders. The condition is progressive, meaning symptoms worsen gradually rather than appearing all at once, which further delays recognition.
Blood tests for GAD65 antibodies are the key diagnostic tool, but interpretation requires context. Low levels of GAD65 antibodies can appear in type 1 diabetes and other conditions without any neurological involvement. The antibody levels seen in SPS are typically much higher, and testing spinal fluid for locally produced antibodies adds further diagnostic certainty. For antibody-negative patients, testing for amphiphysin and glycine receptor antibodies can reveal alternative causes.